BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCDA BioCardia

Market Closed 05-29 16:00:00 EDT

0.9300

+0.0132

+1.44%

盘后0.9300

+0.00000.00%

16:10 EDT

High0.9800	Low0.9130	Vol101.14K
Open0.9400	D1 Closing0.9168	Amplitude7.31%
Mkt Cap10.58M	Tradable Cap8.16M	Total Shares11.37M
T/O96.14K	T/O Rate1.15%	Tradable Shares8.77M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BCDA","market":"US","secType":"STK","nameCN":"BioCardia","latestPrice":0.93,"timestamp":1780084800000,"preClose":0.9168,"halted":0,"volume":101140,"hourTrading":{"tag":"盘后","latestPrice":0.93,"preClose":0.93,"latestTime":"16:10 EDT","volume":7,"amount":6.51,"timestamp":1780085405042,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.014397905759162414,"floatShares":8772500,"shares":11374724,"eps":-0.946888,"marketStatus":"Market Closed","change":0.0132,"latestTime":"05-29 16:00:00 EDT","open":0.94,"high":0.98,"low":0.913,"amount":96144,"amplitude":0.07308,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.946888,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.9168,"preHourTrading":{"tag":"盘前","latestPrice":0.919,"preClose":0.9168,"latestTime":"09:27 EDT","volume":92,"amount":84.5420016,"timestamp":1780061270178,"change":0.0022,"changeRate":0.0024,"amplitude":0.006545},"postHourTrading":{"tag":"盘后","latestPrice":0.93,"preClose":0.93,"latestTime":"16:10 EDT","volume":7,"amount":6.51,"timestamp":1780085405042,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1698436213644257,"impliedVol":0.046,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BCDA/wiki","defaultTab":"wiki","newsList":[{"id":"2638698127","title":"BioCardia says Japan PMDA advice clears path for CardiAMP approval filing in ischemic heart failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698127","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698127?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:04","pubTimestamp":1779969898,"startTime":"0","endTime":"0","summary":"BioCardia received a Japan PMDA consultation record supporting a regulatory submission to seek approval for CardiAMP cell therapy in ischemic HFrEF.PMDA aligned on remaining submission items, including proof patients were on guideline-directed therapy, not eligible for revascularization, and more detail on major outcomes.The company set a seven-month timeline for its PMDA filing, targeting an initial eligible pool of about 20,000 patients in Japan.PMDA flagged post-marketing study expectations tied to patient selection, clinical decision-making, and specialist infrastructure, with MHLW issuing the commercialization certificate.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL8w1yTF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014021.USD","BK4585","LU2095319765.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","SG9999014005.SGD","IE00BN0W2T93.GBP","NDAQ","SG9999014039.USD","BK4139","LU0314104364.USD","IE00BKPKM429.USD","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","BCDA","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698693","title":"BioCardia Announces Japan Pmda Record of Advice Supports Regulatory Submission for Approval of Cardiamp Cell Therapy for Ischemic Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698693?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA4V9W7Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637335096","title":"BioCardia CEO Peter Altman acquires common shares worth $1,570.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2637335096","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637335096?lang=en_us&edition=fundamental","pubTime":"2026-05-22 06:15","pubTimestamp":1779401730,"startTime":"0","endTime":"0","summary":"BioCardia President and CEO Peter Altman reported open-market purchases totaling 1,700 common shares at weighted-average prices of USD 0.95 and USD 0.92.His direct holding increased to 293,266 common shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL4QK7wR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioCardia CEO Peter Altman acquires common shares worth $1,570.00","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333057","title":"BioCardia reports CardiAMP trial improves exercise tolerance in chronic myocardial ischemia patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333057","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333057?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:04","pubTimestamp":1779365062,"startTime":"0","endTime":"0","summary":"BioCardia reported results already presented at EuroPCR from the preliminary open-label cohort of its CardiAMP chronic myocardial ischemia trial.The update showed the minimally invasive cell-therapy procedure was well tolerated, with no major safety issues reported.Patients with refractory angina showed durable improvements in exercise capacity, with fewer angina episodes over follow-up.The readout supports continued clinical development, positioning CardiAMP as a potential option for patients who have exhausted standard drug, catheter-based, or surgical treatments.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDLby3jwd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2095319765.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4139","SG9999014039.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","NDAQ","SG9999014013.SGD","BK4112","SG9999014021.USD","LU2210150020.SGD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","BCDA","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637033374","title":"BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency","url":"https://stock-news.laohu8.com/highlight/detail?id=2637033374","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637033374?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:00","pubTimestamp":1779364800,"startTime":"0","endTime":"0","summary":"– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory ang","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299279/0/en/BioCardia-Announces-CardiAMP-Chronic-Myocardial-Ischemia-Trial-Results-Presented-at-EuroPCR-Showed-Durable-Improvements-in-Exercise-Tolerance-with-Reduced-Angina-Frequency.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636855228","title":"BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase","url":"https://stock-news.laohu8.com/highlight/detail?id=2636855228","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636855228?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:00","pubTimestamp":1779192000,"startTime":"0","endTime":"0","summary":"Miranda Peto, Investor Relations. Email: mpeto@BioCardia.com. Phone: 650-226-0120. Investor Contact:. David McClung, Chief Financial Officer. Email: investors@BioCardia.com. Phone: 650-226-0120","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/19/3297421/0/en/BioCardia-to-Participate-in-a-Fireside-Chat-at-the-Alliance-Global-Partners-A-G-P-Healthcare-Company-Showcase.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","XLV","BK4139","BCDA","LU0128526141.USD","XBI","BK4588","BK4137","LABU","BK4581","HCSG","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636682000","title":"BioCardia CEO Peter Altman acquires 5,700 shares valued at $5,244","url":"https://stock-news.laohu8.com/highlight/detail?id=2636682000","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636682000?lang=en_us&edition=fundamental","pubTime":"2026-05-19 08:20","pubTimestamp":1779150057,"startTime":"0","endTime":"0","summary":"BioCardia President and CEO Peter Altman bought 5,700 common shares at a weighted-average price of $0.92.Altman’s direct stake rose to 291,566 shares following the purchase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL1lfHcQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioCardia CEO Peter Altman acquires 5,700 shares valued at $5,244","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636000961","title":"BioCardia Earnings Call: Progress, Promise and Cash Strain","url":"https://stock-news.laohu8.com/highlight/detail?id=2636000961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636000961?lang=en_us&edition=fundamental","pubTime":"2026-05-19 08:03","pubTimestamp":1779149002,"startTime":"0","endTime":"0","summary":"Biocardia (($BCDA)) has held its Q1 earnings call. Read on for the main highlights of the call. BioCardia’s latest earnings call mixed clear clinic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardia-earnings-call-progress-promise-and-cash-strain?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardia-earnings-call-progress-promise-and-cash-strain?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635053435","title":"BioCardia CEO Peter Altman acquires 5,100 shares for $5,202","url":"https://stock-news.laohu8.com/highlight/detail?id=2635053435","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635053435?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:50","pubTimestamp":1778881824,"startTime":"0","endTime":"0","summary":"BioCardia President and CEO Peter Altman disclosed purchase of 5,100 common shares at weighted average price of USD 1.02.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL9QW9DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioCardia CEO Peter Altman acquires 5,100 shares for $5,202","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635058906","title":"BioCardia Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635058906","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635058906?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:00","pubTimestamp":1778878855,"startTime":"0","endTime":"0","summary":"BioCardia Inc reports results for the quarter ended March 31 - Earnings SummaryBioCardia Inc BCDA.OQ reported a quarterly adjusted loss of 21 cents per share for the quarter ended March 31, higher tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S25M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635084970","title":"BioCardia Q1 EPS $(0.21) Misses $(0.17) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635084970","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635084970?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:20","pubTimestamp":1778847619,"startTime":"0","endTime":"0","summary":"BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 64.41 percent increase over losses of $(0.59) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52593744/biocardia-q1-eps-0-21-misses-0-17-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635845840","title":"BioCardia, Inc. Q1 Net Income USD -2.259 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635845840","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635845840?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:14","pubTimestamp":1778847281,"startTime":"0","endTime":"0","summary":"May 15 (Reuters) - BioCardia, Inc. Q1 operating income USD -2.266 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 15-MAY-202612:00:46.32 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nRSD7D9fS2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635081017","title":"BioCardia Q1 net loss narrows as expenses decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2635081017","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635081017?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:08","pubTimestamp":1778846883,"startTime":"0","endTime":"0","summary":"BioCardia Q1 net loss narrows as expenses declineOverviewUS cellular therapeutics developer's Q1 net loss narrowed from prior yearResearch and development, and SG&A expenses both declined yr/yrCompany","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL1N41S0J1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA","AD","TDS","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635081132","title":"BioCardia Reports First Quarter 2026 Business Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635081132","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635081132?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:00","pubTimestamp":1778846402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUAP6KZ8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635166081","title":"BioCardia, Inc. Q1 Operating Income USD -2.266 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635166081","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635166081?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:00","pubTimestamp":1778846401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLX42B858:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635081977","title":"BioCardia, Inc. Q1 Basic EPS USD -0.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2635081977","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635081977?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:00","pubTimestamp":1778846401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLX42B858:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635790758","title":"BioCardia Inc  expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2635790758","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635790758?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:08","pubTimestamp":1778702887,"startTime":"0","endTime":"0","summary":"BioCardia Inc  expected to post a loss of16cents a share - Earnings Preview BioCardia Inc BCDA.OQ BCDA.O is expected to  report resultson May 15 for the period ending March 31 2026LSEG's mean analyst ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q2PK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634258000","title":"BioCardia schedules first-quarter earnings conference call, corporate update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634258000","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634258000?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:11","pubTimestamp":1778533860,"startTime":"0","endTime":"0","summary":"BioCardia scheduled Q1 2026 financial results release, corporate update conference call for May 15, 2026 at 4:30 PM EDT.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDLzZNkw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4112","LU2210150020.SGD","NDAQ","SG9999014005.SGD","IE00BN0W2W23.USD","BK4139","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014039.USD","BK4585","SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4588","IE00BGHQF748.EUR","BCDA","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634812469","title":"BioCardia provides update on Helix pre-submission meeting with FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2634812469","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634812469?lang=en_us&edition=fundamental","pubTime":"2026-05-09 02:14","pubTimestamp":1778264068,"startTime":"0","endTime":"0","summary":"BioCardia (BCDA) announced the outcome of its pre-submission meeting with FDA on the Helix Transendocardial Delivery Catheter System. FDA agreed th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biocardia-provides-update-on-helix-pre-submission-meeting-with-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biocardia-provides-update-on-helix-pre-submission-meeting-with-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","BK4139","BK4585","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633604451","title":"BioCardia Inc  expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633604451","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633604451?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:07","pubTimestamp":1778245624,"startTime":"0","endTime":"0","summary":"BioCardia Inc  expected to post a loss of16cents a share - Earnings Preview BioCardia Inc BCDA.OQ BCDA.O is expected to  report resultson May 12 (estimated) for the period ending March 31 2026LSEG's m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1FS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocardia.com","stockEarnings":[{"period":"1week","weight":-0.0262},{"period":"1month","weight":-0.1545},{"period":"3month","weight":-0.2791},{"period":"6month","weight":-0.3586},{"period":"1year","weight":-0.5704},{"period":"ytd","weight":-0.256}],"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.066663},{"month":2,"riseRate":0.5,"avgChangeRate":-0.017269},{"month":3,"riseRate":0.25,"avgChangeRate":-0.022375},{"month":4,"riseRate":0.375,"avgChangeRate":0.007226},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.09523},{"month":6,"riseRate":0.25,"avgChangeRate":-0.048165},{"month":7,"riseRate":0.5,"avgChangeRate":-0.016411},{"month":8,"riseRate":0.25,"avgChangeRate":-0.102769},{"month":9,"riseRate":0.375,"avgChangeRate":0.008782},{"month":10,"riseRate":0.375,"avgChangeRate":-0.049332},{"month":11,"riseRate":0.5,"avgChangeRate":0.042585},{"month":12,"riseRate":0.375,"avgChangeRate":-0.012187}],"exchange":"NASDAQ","name":"BioCardia","nameEN":"BioCardia"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioCardia,BCDA,BioCardia股票,BioCardia股票老虎,BioCardia股票老虎国际,BioCardia行情,BioCardia股票行情,BioCardia股价,BioCardia股市,BioCardia股票价格,BioCardia股票交易,BioCardia股票购买,BioCardia股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction